Search
8. Malignant Disease and Immunosuppression
Bendamustine
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA216, TA472 (with obinutuzum)

Busulfan
BNF | BNFC | SPC

Myeloproliferative disorders

Carmustine
BNF | BNFC | SPC

Approved: NICE TA121

Chlorambucil
BNF | BNFC | SPC

Haematological cancers

Rheumatoid arthritis

Cyclophosphamide
BNF | BNFC | SPC
Estramustine
BNF | BNFC | SPC

Prostate Cancer

Ifosfamide
BNF | BNFC | SPC

Metastatic germ cell cancer

Lomustine
BNF | BNFC | SPC

Hodgkin's disease; malignant melanoma; solid tumours

Melphalan
BNF | BNFC | SPC

multiple myeloma, polycythaemia vera, childhood neuroblastoma, advanced ovarian adenocarcinoma, and advanced breast cancer

Thiotepa
BNF | BNFC | SPC

In combination with other chemotherapy

Treosulfan
BNF | BNFC | SPC

Ovarian Cancer

Dactinomycin
BNF | BNFC | SPC

Paediatric cancers

Daunorubicin
BNF | BNFC | SPC

Acute myelogenous leukaemia; acute lymphocytic leukaemia

Advanced AIDS-related Kaposi's sarcoma

 

Doxorubicin
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA389, TA465 (in combination with olaratumab)

Epirubicin
BNF | BNFC | SPC

Oesophagogastric Cancer

Idarubicin
BNF | BNFC | SPC

Acute Myeloid Leukaemia

Mitomycin
BNF | BNFC | SPC

Upper gastro-intestinal and breast cancers; superficial bladder tumours

Mitoxantrone
BNF | BNFC | SPC

Multiple Sclerosis

Pixantrone
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA306

Azacitidine
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA218

Not Approved: NICE TA399

Capecitabine
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA61, TA100, TA191

Cladribine
BNF | BNFC | SPC

Tariff Excluded; NHSE Commissioned

Approved: NICE TA493

Clofarabine
BNF | BNFC | SPC

Acute myeloid leukaemia

Cytarabine
BNF | BNFC | SPC

Acute myeloblastic leukaemia

Liposomal cytarabine-daunorubicin
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA552 - for untreated acute myeloid leukaemia

Fludarabine
BNF | BNFC | SPC

NHSE Commissioned (Ca indications)

Approved: NICE TA29

Not Approved: NICE TA119

Fluorouracil
BNF | BNFC | SPC

Injection and Infusion vials

Approved: NICE TA100, TA176

Not Approved: NICE TA118, TA440

Gemcitabine
BNF | BNFC | SPC

NHSE Commissioned (Ca indications)

Approved: NICE TA116, TA476

Not Approved: NICE TA389

Mercaptopurine
BNF | BNFC | SPC

Ca indications

Nelarabine
BNF | BNFC | SPC

T-cell acute lymphoblastic leukaemia; T-cell lymphoblastic lymphoma

Pemetrexed
BNF | BNFC | SPC

Approved: NICE TA135, TA181, TA190, TA402

Not Approved: NICE TA124 (patients who have had prior chemotherapy)

Tioguanine
BNF | BNFC | SPC

Acute leukaemia; Chronic myeloid leukaemia

Vinblastine
BNF | BNFC | SPC

Variety of cancers including leukaemias, lymphomas and some solid tumours

Vincristine
BNF | BNFC | SPC

Variety of cancers including leukaemias, lymphomas and some solid tumours

Vindesine
BNF | BNFC | SPC

Variety of cancers including leukaemias, lymphomas and some solid tumours

Vinflunine
BNF | BNFC | SPC

NHSE Commissioned

Not Approved: NICE TA272

Vinorelbine
BNF | BNFC | SPC

Advanced Breast Cancer; Advanced Non-small Cell Lung Cancer

Abemaciclib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA579 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

Aflibercept
BNF | BNFC | SPC

Tariff Excluded; CCG Commissioned in Ophthalmology. NHSE Commissioned in Cancer.

Approved: NICE TA294, TA305, TA346, TA409, TA486

Not Approved: NICE TA307

Alectinib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE: TA536 - Untreated ALK-positive advanced non-small-cell lung cancer

Arsenic trioxide
BNF | BNFC | SPC

Acute promyelocytic leukaemia

Tariff-Excluded (Ca indications); NHSE commissioned

Approved: NICE TA526

Axitinib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA333

Bevacizumab
BNF | BNFC | SPC

NHSE Commissioned (Ca indications)

Not approved: NICE TA118TA178, TA212, TA214, TA242TA263TA284, TA285

Bexarotene
BNF | BNFC | SPC

Skin manifestations of cutaneous T-cell lymphoma

Bortezomib
BNF | BNFC | SPC

NHSE Commissioned (Ca indications)

Approved: NICE TA129TA228, TA311, TA370

Brentuximab vedotin
BNF | BNFC | SPC

NICE NHSE Commissioned for Cancer indications

CD30-positive Hodgkin lymphoma

Approved: NICE TA446 as a treatment option for CD30-positive Hodgkin lymphoma in adults under the conditions specified within the TA.

Approved: NICE TA478 as a treatment option for relapsed or refractory systemic anaplastic large cell lymphoma in adults under the conditions specified within the TA.

Approved: NICE TA524 recommended as an option for treating CD30‑positive Hodgkin lymphoma in adults with relapsed or refractory disease, only if they have already had autologous stem cell transplant or they have already had at least 2 previous therapies when autologous stem cell transplant or multi-agent chemotherapy are not suitable.

Approved: NICE TA577 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma

Brigatinib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA571 - Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib

Ceritinib
BNF | BNFC | SPC

Tariff-excluded; NHSE commissioned

Untreated anaplastic lymphoma kinase (ALK)‑positive advanced non-small-cell lung cancer in adults

Approved: NICE TA395TA500

Cetuximab
BNF | BNFC | SPC

Tariff-Excluded drug; NHSE commissioned

Approved: NICE TA145, TA439, TA473

Not Approved: NICE TA118, TA242

Crisantaspase
BNF | BNFC | SPC

Acute lymphoblastic leukaemia

Dacarbazine
BNF | BNFC | SPC

Metastatic melanoma and soft tissue sarcomas

Daratumumab
BNF | BNFC | SPC

Tariff-Excluded (Ca indications); NHSE Commissioned

Approved: NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma

Approved: NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma

Durvalumab
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA578 Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

Eribulin
BNF | BNFC | SPC

Tariff-Excluded (Ca indications); NHSE Commissioned

Approved: NICE TA423

Not Approved: NICE TA515

Gemtuzumab
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia

Hydroxycarbamide
BNF | BNFC | SPC

Chronic Myeloid Leukaemia; Cancer of the cervix; sickle-cell disease

Inotuzumab ozogamicin
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA541 - Treating relapsed or refractory B-cell acute lymphoblastic leukaemia

Ipilimumab
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA268, TA319, TA400

Ixazomib
BNF | BNFC | SPC

Tariff-Excluded; NHSE commissioned

Relapsed or refractory multiple myeloma

Approved: NICE TA505 (with lenalidomide and dexamethasone)

 

Lutetium (177Lu) oxodotreotide
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours  

Mitotane
BNF | BNFC | SPC

Advanced or inoperable adrenocortical carcinoma

Niraparib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA528 - Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer

Nivolumab
BNF | BNFC | SPC

NHSE Commissioned for Cancer indications

Approved:

  • NICE TA384: as a monotherapy treatment option for advanced (unresectable or metastatic) melanoma in adults.
  • NICE TA400: as a treatment option in combination with ipilimumab for advanced (unresectable or metastatic) melanoma in adults, only when the company provides ipilimumab with the discount agreed in the patient access scheme.
  • NICE TA417: as a treatment option for previously treated advanced renal cell carcinoma in adults, when the company provides nivolumab in line with the commercial access agreement with NHS England.
  • NICE TA462: as a treatment option for relapsed or refractory classical Hodgkin lymphoma under conditions specified within the TA.
  • The indications listed below are funded by Cancer Drugs Fund in accordance with the following NICE TAs
  • NICE TA483: as a treatment option for locally advanced or metastatic squamous non-small-cell lung cancer under conditions specified within the TA.
  • NICE TA484:: as a treatment option for locally advanced or metastatic squamous non-small-cell lung cancer under conditions specified within the TA.
  • NICE TA490: as a treatment option for squamous cell carcinoma of the head and neck under conditions specified within the TA.
  • NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
  • NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma

Not approved:

  • NICE TA530: Nivolumab is not recommended, within its marketing authorisation, for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing therapy
Olaparib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA381

Palbociclib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA495

Panitumumab
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA439 

Not Approved: NICE TA242

Pegaspargase
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA408

Pembrolizumab
BNF | BNFC | SPC

Tariff-Excluded; NHSE commissioned

Melanoma, Non-small-cell lung cancer, urothelial carcinoma

Approved: NICE TA357 - advanced melanoma after disease progression with ipilimumab

Approved: NICE TA366 - advanced melanoma not previously treated with ipilimumab

Approved: NICE TA428 - PD-L1-positive non-small-cell lung cancer after chemotherapy

Approved: NICE TA447 - untreated PD-L1-positive metastatic non-small-cell lung cancer

Approved: NICE TA519 - locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

Approved: NICE TA522 - Untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

Approved: NICE TA531 - Untreated PD-L1-positive metastatic non-small-cell lung cancer

Approved: NICE TA540 - Relapsed or refractory classical Hodgkin lymphoma

Approved: NICE TA553 - for adjuvant treatment of resected melanoma with high risk of recurrence. Cancer Drugs Fund is the responsible commissioner.

 

Pentostatin
BNF | BNFC | SPC

Hairy cell leukaemia

Pertuzumab
BNF | BNFC | SPC

Tariff-Excluded Drug (Ca indications); NHSE Commissioned

Approved: NICE TA424, TA509 (with trastuzumab and docetaxel)

Approved: NICE TA569 - Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer

Porfimer
BNF | BNFC | SPC

Non-small cell lung cancer; oesophageal cancer

Procarbazine
BNF | BNFC | SPC

Hodgkin's disease

Ramucirumab
BNF | BNFC | SPC

NHSE Commissioned

Not approved: NICE TA378, TA403

Ribociclib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA496

Sorafenib
BNF | BNFC | SPC

Tariff-Excluded; NHSE Commissioned

Approved: NICE TA474

Approved: NICE TA535 - Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine

Not Approved: NICE TA178, TA189

 

Talimogene laherparepvec
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA410

Temozolomide
BNF | BNFC | SPC

Tariff Excluded (Ca indications); NHSE Commissioned

Approved: NICE TA23, TA121

Tisagenlecleucel
BNF | BNFC | SPC

Cancer Drug Fund is the responsible commissioner.

Approved: NICE TA554 Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years      

Approved: NICE TA567 Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies

Trabectedin
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA185

Not Approved: NICE TA389

Trametinib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA396

Trastuzumab
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA34, TA208, TA458, TA509 (with pertuzumab and docetaxel)

Not Approved: NICE TA257

Trifluridine - tipiracil
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA405

Venetoclax
BNF | BNFC | SPC

NHSE Commissioned for Cancer indications

Approved: NICE TA487

Vismodegib
BNF | BNFC | SPC

NHSE Commissioned for Cancer indications

Not Approved: NICE TA489

Carboplatin
BNF | BNFC | SPC

Approved: NICE TA389

Cisplatin
BNF | BNFC | SPC

Approved: NICE TA191, TA183

Oxaliplatin
BNF | BNFC | SPC

NHSE Commissioned (Ca indications)

Approved: NICE TA100, TA176

Afatinib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA310

Bosutinib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA401 Bosutinib for previously treated chronic myeloid leukaemia

Not approved: NICE TA576 Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)

Cabozantinib
BNF | BNFC | SPC

Tariff-Excluded (Ca indications): NHSE Commissioned

Approved: NICE TA463 - Cabozantinib for previously treated advanced renal cell carcinoma

Approved: NICE TA516 - Cabozantinib for treating medullary thyroid cancer

Approved: NICE TA542 - Cabozantinib for untreated advanced renal cell carcinoma

Not approved: NICE TA582 - Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal)

Crizotinib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA406 - Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

Approved: NICE TA422 - Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

Approved: NICE TA529 - Treating ROS1-positive advanced non-small-cell lung cancer

Dabrafenib
BNF | BNFC | SPC

Tariff Excluded; NHSE Commissioned

Approved: NICE TA321 - Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma

Approved: NICE TA544 - Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma

Dasatinib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA425, TA426

Erlotinib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA258, TA374

Not Approved: NICE TA227

Everolimus
BNF | BNFC | SPC

Tariff-Excluded; NHSE Commissioned

Metastatic advanced PNETs

Approved: NICE TA421 (with exemestane), TA432, TA449 (with sunitinib), TA498 (with lenvatinib)

Not Approved: NICE TA219, TA348, TA481, TA482

Gefitinib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA192, TA374

Ibrutinib
BNF | BNFC | SPC

NHSE commissioned for Cancer indications

Approved: NICE TA429TA491, TA502

Idelalisib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA359

 

Imatinib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA70, TA86, TA326, TA426

Not Approved: NICE TA209, TA425

Lapatinib
BNF | BNFC | SPC

Advanced breast Ca

Not Approved: NICE TA257

Lenvatinib
BNF | BNFC | SPC

Tariff-excluded; NHSE commissioned

Approved: NICE TA498 - with everolimus for previously treated advanced renal cell carcinoma

Approved: NICE TA535 - and sorafenib for treating differentiated thyroid cancer after radioactive iodine

Approved: NICE TA551- for untreated advanced hepatocellular carcinoma

Midostaurin
BNF | BNFC | SPC

Tariff Excluded (Ca indications); NHSE commissioned

Approved: NICE TA523

Nilotinib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA425, TA426

Nintedanib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA347, TA379

Pazopanib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA215

Ponatinib
BNF | BNFC | SPC

Tariff Excluded; NHSE Commissioned

Chronic myeloid leukaemia, acute lymphoblastic leukaemia

Approved: NICE TA451

Regorafenib
BNF | BNFC | SPC

Tariff Excluded; NHSE Commissioned

Approved: NICE TA488

Not Approved: NICE TA514

Ruxolitinib
BNF | BNFC | SPC

Tariff Excluded; NHSE Commissioned

Approved: NICE TA386

 

Sunitinib
BNF | BNFC | SPC

Tariff-Excluded; NHSE Commissioned

Approved: NICE TA169, TA179, TA449 (with everolimus)

Not Approved: NICE TA178

Temsirolimus
BNF | BNFC | SPC

Tariff Excluded; NHSE Commissioned

Not Approved: NICE TA178

Tivozanib
BNF | BNFC | SPC

Tariff-Excluded (Ca indications); NHSE Commissioned

Approved - NICE TA512

Vemurafenib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA269

Not Approved: NICE TA414 (in combination with cobimetinib)

Cabazitaxel
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA391

Docetaxel
BNF | BNFC | SPC

NHSE Commissioned (Ca indications)

Approved: NICE TA101, TA109, TA509 (with pertuzumab and trastuzumab)

Paclitaxel
BNF | BNFC | SPC

Tariff Excluded (Ca indications); NHSE Commissioned

Approved: NICE TA34 (with paclitaxel), TA55 (with cisplatin or carboplatin), TA91, TA116, TA389TA476

Not Approved: NICE TA108, TA360

Irinotecan (pegylated liposomal)
BNF | BNFC | SPC

Advanced colorectal Ca; Metastatic colorectal Ca

Not Approved: NICE TA307 (in combination with aflibercept and fluorouracil-based therapy), TA440

Topotecan
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA183, TA184,

Not Approved: NICE TA389

Palifermin
BNF | BNFC | SPC

Oral mucositis

Calcium Folinate
BNF | BNFC | SPC

Adjuvant to mtx and 5-FU chemotherapy

Calcium Levofolinate
BNF | BNFC | SPC

Prevention of methotrexate-induced side effects

Suspected methotrexate overdose

Adjunct to fluorouracil in colorectal cancer

Calcium Levomefolate
BNF | BNFC | SPC

Homocysteine remethylation defect

Dexrazoxane
BNF | BNFC | SPC

Anthracycline extravasation

NICE TA85, NICE TA99

Carfilzomib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA457

Necitumumab
BNF | BNFC | SPC

NHSE Commissioned

Not Approved: NICE TA411

Mycophenolate Mofetil
BNF | BNFC | SPC

Capsules 250mg, 500mg

Shared Care (Amber) as per guidelines:

Nephrology Shared Care Guideline

Rheumatology Shared Care Guideline

NHSE Commissioned in Transplant Immunosuppression:

Approved: NICE TA481, TA482

First choice for most indications

Basiliximab
BNF | BNFC | SPC

Tariff Excluded; NHSE Commissioned

Approved: NICE TA481, TA482

Belatacept
BNF | BNFC | SPC

NHSE Commissioned

Not Approved: NICE TA481, TA482

Ciclosporin (Neoral)
BNF | BNFC | SPC

Capsules 25mg, 50mg

Shared Care

Dermatology Shared Care Guideline

Nephrology Shared Care Guideline

Rheumatology Shared Care Guideline

Important safety information: Patients should be stabilised on a particular brand of oral ciclosporin because switching between formulations without close monitoring may lead to clinically important changes in the blood-ciclosporin concentration

Tacrolimus
BNF | BNFC | SPC

Capsules 500 microgram, 1mg

Important Safety Information: MHRA/CHM Advice - Oral tacrolimus products to be prescribed by brand name only, to minimise the risk of inadvertent switching between products which has been associated with reports of toxicity and graft rejection (June 2012)

NHSE Commissioned in Transplant Immunosuppression

Approved: NICE TA481, TA482

Sirolimus
BNF | BNFC | SPC

Renal transplantation

Not Approved: NICE TA481TA482

Alemtuzumab
BNF | BNFC | SPC

Tariff Excluded; NHSE Commissioned

Approved: NICE TA312

Avelumab
BNF | BNFC | SPC

NHSE Commissioned (Ca indications)

Approved: NICE TA517

Blinatumomab
BNF | BNFC | SPC

Tariff-Excluded; NHSE Commissioned

Philadelphia-chromosome-negative acute lymphoblastic leukaemia

Approved: NICE TA450

Obinutuzumab
BNF | BNFC | SPC

Tariff-Excluded (Ca indication); NHSE Commissioned

Approved: NICE TA343, TA472, TA513

Ocrelizumab
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA533 - treating relapsing–remitting multiple sclerosis

Approved: NICE TA585 - Ocrelizumab for treating primary progressive multiple sclerosis

Ofatumumab
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA344

Not Approved: NICE TA202

 

Olaratumab
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA465 (in combination with doxorubicin)

Atezolizumab
BNF | BNFC | SPC

NHSE Commissioned (Ca indications)

Approved: NICE TA492 - Untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

Approved: NICE TA520 - Treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy

Approved: NICE TA525 - Treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

Approved: NICE TA584 - Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer

Canakinumab
BNF | BNFC | SPC

Terminated Appraisal: NICE TA281

Cobimetinib
BNF | BNFC | SPC

NHSE Commissioned

Not Approved: NICE TA414 (in combination with vemurafenib)

Dimethyl fumarate capsules (Tecfidera)
BNF | BNFC | SPC

Tariff-excluded; NHSE commissioned

Approved: NICE TA320 (relapsing-remitting multiple sclerosis)

 

 

Dimethyl fumarate tablets (Skilarence)
BNF | BNFC | SPC

Tariff-excluded; CCG commissioned

Approved: NICE TA475 (moderate to severe plaque psoriasis in adults)

NTAG Decision Summary Feb 2017: Dimethyl fumarate is recommended for moderate to severe chronic plaque psoriasis

Fingolimod
BNF | BNFC | SPC

Tariff Excluded; NHSE Commissioned

Approved: NICE TA254

Glatiramer
BNF | BNFC | SPC

Multiple sclerosis

Tariff-Excluded; NHSE commissioned

Approved:NICE TA527

Interferon alfa
BNF | BNFC | SPC

Tariff Excluded; NHSE Commissioned

Approved: NICE TA75

Interferon beta
BNF | BNFC | SPC

Multiple sclerosis

Tariff Excluded; NHSE Commissioned

Approved: NICE TA527 (Interferon beta-1a, Interferon beta‑1b (Extavia))

Not Approved: NICE TA527 (Interferon beta‑1b (Betaferon))

 

Lenalidomide
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA171 - Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies

Approved: NICE TA322 - Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality

Approved: NICE TA505 - Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma

Approved: NICE TA586 - Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib

Approved: NICE TA587 - Lenalidomide plus dexamethasone for previously untreated multiple myeloma

Mifamurtide
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA235

Natalizumab
BNF | BNFC | SPC

Tariff Excluded; NHSE Commissioned

Approved: NICE TA127

Osimertinib
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA416

Panobinostat
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA380

Peginterferon Alfa
BNF | BNFC | SPC

Tariff Excluded; NHSE Commissioned

Approved: NICE TA75TA96TA106, TA200, TA300

Pomalidomide
BNF | BNFC | SPC

Tariff-Excluded (NHSE commissioned)

Approved: NICE TA427

Not Approved: NICE TA338 (updated and replaced by TA427)

 

Teriflunomide
BNF | BNFC | SPC

Tariff Excluded; NHSE Commissioned

Approved: NICE TA303

Thalidomide
BNF | BNFC | SPC

Tariff Excluded; NHSE Commissioned

Approved: NICE TA228

Dinutuximab beta
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA538 - Dinutuximab beta for treating neuroblastoma

NICE TA112

Anastrozole
BNF | BNFC | SPC

Tablets 1mg

Exemestane
BNF | BNFC | SPC

Tablets 25mg

Approved: NICE TA421 (with everolimus)

Fulvestrant
BNF | BNFC | SPC

Not Approved: NICE TA239, TA503

Letrozole
BNF | BNFC | SPC

Tablets 2.5mg

Tamoxifen
BNF | BNFC | SPC

Tablets 20mg

Abiraterone Acetate
BNF | BNFC | SPC

Tablets 250mg

Approved: NICE TA259, TA387

Bicalutamide
BNF | BNFC | SPC

Tablets 50mg, 150mg

Cyproterone
BNF | BNFC | SPC

Tablets 50mg

This drug is Amber (to be initiated in secondary care), but there is no Shared Care protocol to follow

Degarelix
BNF | BNFC | SPC

Injection 80mg, 120mg

This drug is Amber (to be initiated in secondary care), but there is no Shared Care protocol to follow

Approved in line with NICE TA404

Flutamide
BNF | BNFC | SPC

Tablets 250mg

Goserelin Injection
BNF | BNFC | SPC

Implant 3.6mg and 10.8mg

Endometriosis, Breast Ca, Prostate Ca

Specialist initiation only

This drug is Amber (to be initiated in secondary care), but there is no Shared Care protocol to follow.  First injection to be given by trust.

Leuprorelin Acetate
BNF | BNFC | SPC

Injection 3.75mg, 11.25mg

Prostate Cancer

This drug is Amber (to be initiated in secondary care), but there is no Shared Care protocol to follow.  First injection to be given by trust.

Radium-223 dichloride
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA412

Triptorelin
BNF | BNFC | SPC

Prostate Cancer

Enzalutamide
BNF | BNFC | SPC

NHSE Commissioned

Approved: NICE TA316, TA377

Lanreotide Acetate
BNF | BNFC | SPC

Injection 60mg (Somatuline autogel)

Liver Disease

 

Octreotide (Other Indications)
BNF | BNFC | SPC

Injection 100 microgram, 500microgram, depot injection 20mg

 

Octreotide (Palliative Care)
BNF | BNFC | SPC

 Symptomatic reduction of tumour related secretions, Inoperable bowel obstruction in patients with cancer, Intractable diarrhoea related to high output ileostomies or entero-cutaneous fistulae

Shared Care Guideline

For all other indications, this drug is Red